POLYCYSTIC KIDNEY DISEASE – RESULTS AND ANALYSIS OF PERSONAL EXPERIENCE
DOI:
https://doi.org/10.11603/2414-4533.2025.1.15182Keywords:
polycystic kidney disease, kidney transplantation, hemodialysis, waiting list, multidisciplinary approachAbstract
The aim of the work: to give importance to multidisciplinary treatment of patients with polycystic kidney disease and to show acceptable levels of frequency of intraoperative and postoperative complications.
Materials and Methods. We examined 58 patients with polycystic kidney disease at the Department of Transplantation and Abdominal Surgery of the Heart Institute of the Ministry of Health of Ukraine and the Volyn Regional Hospital in Lutsk during the observation period 2021–2023. In 52 of them, the hereditary genesis of the disease was established, while in the rest – was not. Among the patients, the proportion of men was 52% (30 patients), women – 48% (28 patients). The average age of the patients was 46 years, while the youngest patient was 19 years old, the oldest – 73 years old.
Results. Polycystic kidney disease is a rather complex disease from the point of view of transplantation management. The presence of polycystic transformed kidneys is a relative contraindication for transplantation. First, the large and gigantic size of the kidneys does not allow placing the transplant in the retroperitoneal space, since the probable contact of the transplant with the polycystic transformed kidney of the recipient. Second, after the appointment of immunosuppressive therapy, there is a high risk of graft loss by the recipient. Third, the vast majority of patients with CKD are either already receiving renal replacement therapy, or the probability of needing renal replacement therapy is extremely high. Considering that kidney transplantation is the method of choice in renal replacement therapy, providing patients with kidney disease with this treatment is a serious clinical problem and requires a modern clinical approach.
References
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007; 369:1287-301. DOI: https://doi.org/10.1016/S0140-6736(07)60601-1
Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015; 88:17-27.
United States Renal Data System. 1995 Annual Report. US Department of Health and Human Services, 1995: 30.
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095-128. DOI: https://doi.org/10.1016/S0140-6736(12)61728-0
Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis [Electronic resource]. PLoS One. 2016; 11(7). DOI: 10.1371/journal.pone.0158765. DOI: https://doi.org/10.1371/journal.pone.0158765
Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease: the polycystins revisited. Kidney Int. 2015; 88(4):699-710. DOI: 10.1038/ki.2015.207. DOI: https://doi.org/10.1038/ki.2015.207
Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015; 88(1):17-27. DOI: 10.1038/ki.2015.59. DOI: https://doi.org/10.1038/ki.2015.59
Chebib FT , Torres VE . Recent advances in the management of autosomal dominant polycystic kidney disease[J]. Clin J Am Soc Nephrol, 2018,13(11):1765-1776. DOI: 10.2215/CJN.03960318. DOI: https://doi.org/10.2215/CJN.03960318
Polycystic Kidney Disease Treatment & ManagementAvailable from: https://emedicine.medscape.com/article/244907-treatment? form=fpf.
Chadban SJ, Ahn C, Axelrod DA. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. PMID: 32224812. PMCID: PMC7147399. DOI: 10.1097/TP.0000000000003137. DOI: https://doi.org/10.1097/TP.0000000000003137
Li L, Szeto CC, Kwan BC, et al. Peritoneal dialysis as the first-line renal replacement therapy in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2011; 57(6):903-07. DOI: 10.1053/j.ajkd.2011.01.019. DOI: https://doi.org/10.1053/j.ajkd.2011.01.019
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 М. С. ЗАГРІЙЧУК, М. О. КОНДРАТЮК, Р. А. САМОКІЩУК, М. І. КОРШУНОВА
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish their work in Hospital Surgery. Journal by L. Ya. Kovalchuk agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
